By Brendan Pierson
NEW YORK (Reuters) - The fate of former drug company executive Martin Shkreli now rests with jurors in Brooklyn federal court, who will begin deliberating Monday morning after a month-long trial.
Shkreli, 34, is best known for raising the price of anti-infection drug Daraprim by 5,000 percent in 2015 as chief executive of Turing Pharmaceuticals. The increase sparked outrage from U.S. lawmakers and patients and earned Shkreli the nickname "pharma bro."
The charges he now faces relate not to Turing but to Shkreli's management of his previous drug company, Retrophin Inc, and hedge funds MSMB Capital and MSMB Healthcare, between 2009 and 2014. Prosecutors claim he lied to MSMB investors, lost their money and paid them back with cash and stock stolen from Retrophin.
- PHOTOS: New art and old relics at Mickey Mouse's NYC gallery 25 Pictures
- PHOTOS: See Yes on 3 supporters react to historic transgender rights Question 3 win 11 Pictures
- PHOTOS: A look back at Queen performing in the 1970s and 1980s 22 Pictures
- All of these celebrities have had their nudes leaked 35 Pictures
- PHOTOS: A look at Idris Elba's style through the years 20 Pictures
- PHOTOS: Heidi Klum's annual Halloween party and other amazing celebrity costumes 17 Pictures
- These are the spookiest cities per capita in the U.S. 5 Pictures
- Food Network star talks pumpkin carving 1 Pictures
- Who is Alexander Edwards, Amber Rose's new boyfriend? 9 Pictures
- Is Cardi B pregnant again? This tweet has people guessing 6 Pictures
- Natural Museum's best wildlife photos of the year 5 Pictures
On Friday, jurors finished hearing lawyers' closing arguments in the case.
"Maybe Martin could have been more responsive to the needy investors," said Benjamin Brafman, Shkreli's lawyer. "Maybe because of the way his mind operates at warp speed, he was doing too many things at one time."
But Brafman urged jurors to see Shkreli as an eccentric genius, driven by his desire to build a drug company that would save lives. He stressed that the investors made money in the end.
In a rebuttal, Assistant U.S. Attorney Jacquelyn Kasulis said Brafman was describing a "mythological Martin Shkreli."
"He knew exactly what he was doing," she said. "We have proven his intent to deceive beyond any doubt."
She described Shkreli as "calculating," saying he told investors what they wanted to hear so they would hand over their money.
Kasulis told the jurors it did not matter that Shkreli's hedge fund investors were paid back by Retrophin.
"If you rob a bank, and then you rob another bank to pay back the first back, you still robbed that first bank," she said.
Shkreli, who did not testify in his defense, has often seemed to revel in his public reputation, posting on social media even as his trial unfolded.
"My case is a silly witch hunt perpetrated by self-serving prosecutors," he posted on Facebook Thursday, after the first part of Brafman's argument. "Thankfully my amazing attorney sent them back to junior varsity where they belong. Drain the swamp. Drain the sewer that is the (U.S. Department of Justice). MAGA."
"MAGA" is widely used as an acronym for "Make America Great Again," President Donald Trump's campaign slogan.
(Reporting by Brendan Pierson in New York; Editing by Lisa Shumaker)